MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm® Contrast Biopsy Software, which combines contrast-enhanced diagnostic ...

Hologic, Inc. HOLX recently announced the addition of improved features to its Brevera Breast Biopsy System with CorLumina Imaging Technology. Notably, the system was launched in 2017 and has been ...

After COVID-19 testing sales pushed the company’s quarterly income to over $1.3 billion last year, Hologic is beginning to spend some of that cash—albeit conservatively. The company kicked off 2021 ...

Hologic has paid $64 million to buy a German biopsy health technology firm, the Marlborough medical device maker said Monday, giving it the second acquisition of roughly that size in the past five ...

Global Core Needle Biopsy Devices Market Trends 2023: This research elaborates on the industrial trends for topmost industries for the insights on Core Needle Biopsy Devices market, observes ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) will virtually showcase its extensive portfolio of breast and skeletal health products, including screening, surgical, interventional, ...

A new private-label deal will see Hologic Inc. distributing a soft tissue biopsy instrument manufactured by Angiotech Pharmaceuticals Inc. Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) inked a three-year ...

Hologic (HOLX) said that achieving the 2026 milestone under its  CVR agreement with its sale to Blackstone (BX)  and TPG (TPG ...

Dublin, Sept. 07, 2020 (GLOBE NEWSWIRE) -- The "China Biopsy Market, by Cancer Segment, Volume of Biopsy and Patient Diagnosed Numbers, Company Analysis" report has been added to ...

Hologic (HOLX) announced that its Affirm Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate ...